CTYPE html> ProCanBio | Biomarker Card

Biomarker Card

This biomarker card gives comprehensive information about each biomarker.
Detailed Information
Biomarker ID1141
PMID23798998
Year2013
Biomarkerlet-7a; let-7b; let-7c, miR-515-3p; miR515-5p; miR-181b; miR-146b; miR-361
Biomarker BasisExpression Based
BiomoleculemiRNA
SourceTissue
SubjectsHumans
RegulationUpregulated: [let-7a - 1.7 fold; let-7b 3.7 fold; let-7c 3.0 fold, miR-515-3p 3.2 fold; miR515-5p 3.2 fold;] Downregulated: [miR-181b 1.8 fold; miR-146b 1.7 fold; miR-361 1.7 fold]
Odds Ratio/Hazard Ratio/Relative RiskNA
Effect on PathwaysPathways Include(let-7a):- nucleoplasm; regulation of RNA metabolic process; DNA-binding transcription factor activity, RNA polymerase II-specific; regulation of nucleic acid-templated transcriptionregulation of transcription, DNA-templated Pathways Include(let-7c):- regulation of RNA metabolic process; regulation of nucleic acid-templated transcription; regulation of RNA biosynthetic process; RNA biosynthetic process; regulation of transcription, DNA-templated Pathways Include( miR-515-3p):- synapse; DNA-binding transcription factor activity; transcription regulatory region DNA binding; transferase activity; DNA-binding transcription factor activity, RNA polymerase II-specific Pathways Include(miR-515-5p):-DNA-binding transcription factor activity, RNA polymerase II-specific; nuclear chromatin; RNA biosynthetic process; regulation of RNA biosynthetic process; regulation of nucleic acid-templated transcription
ExperimentClinical progression free survival (CPFS) Vs. clinical failure (CF)
Type of BiomarkerPrognostic
Cohort7 patients in High Risk PCa with CPFS and 6 which were high risk with Clinical Failure were included in the study
SenstivityNA
SpecificityNA
AUCNA
AccuracyNA
Level Of Significancep<0.05
Method Usedmicroarray
ClinicalNo
RemarksNA
Clinical Trial NumberNA
Degree Of ValidityValidated on independent patient dataset
Technical Namelet-7a, let-7b, let-7c, miR-515-3p, miR515-5p, miR-181b, miR-146b, miR-361